MGAT2-IN-1

• CAT Number: I013226
• CAS Number: 1800025-30-2
• Molecular Formula: C₂₇H₂₁ClF₅N₇O₃S
• Molecular Weight: 654.01
• Purity: ≥95%
• Target: Acyltransferase
• Solubility: DMSO
• IUPAC Name: N-(4-chloro-2,6-difluorophenyl)-1-[5-[2-methyl-5-(trifluoromethyl)pyrazol-3-yl]pyrimidin-2-yl]-7-(2-oxopyrrolidin-1-yl)-2,3-dihydroindole-5-sulfonamide
• InChI: InChI=1S/C27H21ClF5N7O3S/c1-38-20(11-22(36-38)27(31,32)33)15-12-34-26(35-13-15)40-6-4-14-7-17(10-21(25(14)40)39-5-2-3-23(39)41)44(42,43)37-24-18(29)8-16(28)9-19(24)30/h7-13,37H,2-6H2,1H3
• InChIKey: VSZRYLHBOKTNBO-UHFFFAOYSA-N
• SMILES: CN1C(=CC(=N1)C(F)(F)F)C2=CN=C(N=C2)N3CCC4=CC(=CC(=C43)N5CCCC5=O)S(=O)(=O)NC6=C(C=C(C=C6F)Cl)F

MGAT2-IN-1(CAT: I013226) is a potent and selective inhibitor of monoacylglycerol acyltransferase 2 (MGAT2), an enzyme critical in triglyceride biosynthesis. By inhibiting MGAT2, this compound reduces dietary fat absorption and lipid accumulation, making it an invaluable tool for studying metabolic diseases such as obesity, diabetes, and non-alcoholic fatty liver disease (NAFLD). MGAT2-IN-1 is widely utilized in in vitro and in vivo models to explore lipid metabolism pathways and their therapeutic modulation. With high specificity, purity, and stability, it supports research into novel treatments for metabolic disorders and contributes to advancements in metabolic disease drug discovery.